Loading
A phase 2 trial of Nivolumab, Bevacizumab in colorectal cancer, run by Gilead Sciences, now recruiting.
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer is a phase 2 interventional study registered as NCT07527858 by Gilead Sciences, with 170 participants planned, started 2026-05-19 and due to reach its primary completion in 2028-12. Interventions recorded: Denikitug, Nivolumab, Bevacizumab, Trifluridine-Tipiracil. Conditions listed: Advanced Microsatellite Stable Colorectal Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Gilead Sciences (incl. Kite), Immune checkpoint inhibitors.
Shares Gilead Sciences (incl. Kite), Bevacizumab.
Shares Gilead Sciences (incl. Kite), Immune checkpoint inhibitors.
Shares Gilead Sciences (incl. Kite), Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/